McCormick’s Q2 Beat Lifts Near-Term Sentiment, but Unilever Deal Overhang Keeps Risk Elevated

What happened

McCormick’s Q2 2026 results surpassed expectations, driven by the McCormick de México acquisition, organic pricing, and supply chain savings, while the pending $44.8 billion Unilever Foods combination promises mid- to high-teens EPS accretion by year three. However, the DeepValue master report maintains a WAIT rating, as the $15.7 billion cash financing requirement, antitrust divestiture risk, and sluggish organic volumes still overhang the stock. The Seeking Alpha article argues the shares are undervalued by 19% with durable earnings and a 40-year dividend growth streak, but that thesis hinges on deal execution with no major regulatory remedies. The Q2 beat confirms near-term operational resilience, yet it does not alter the binary nature of the Unilever transaction or the strain of short-term borrowings that have already risen to $1.31 billion. Investors must balance this improved operational momentum against the unchanged structural risks and wait for clearer deal milestones.

Implication

The Q2 earnings beat and margin expansion demonstrate that McCormick’s core business is executing despite competitive promotions and volume headwinds. However, the stock’s path remains dominated by the Unilever combination, where a $15.7 billion bridge loan, antitrust scrutiny, and potential divestitures inject significant uncertainty. The Seeking Alpha buy thesis relies on deal closure and synergy realization without major regulatory concessions, a scenario the master report only assigns a 20% probability to in its bull case. Until management files the S-4, schedules a shareholder vote, and terms out the bridge financing, the stock is likely to trade on deal headlines rather than fundamental progress. Consequently, we only recommend adding exposure on dips toward $45 or upon definitive de-risking events.

Thesis delta

The Q2 2026 beat and optimistic buy-side commentary modestly strengthen the bull case for McCormick’s standalone operations, but they do not address the central deal-execution risks that underpin our WAIT rating. The investment thesis remains contingent on observable de-risking of the Unilever transaction, which has not yet occurred. Therefore, while the stock may trade a bit higher on improved sentiment, the margin of safety for new capital deployment has not widened enough to upgrade our stance.